Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.
A new model of company creation pioneered by Lilly, Celgene, Sanofi, Roche and others is set to deliver both clinical candidates and platform technologies.
Chronic lymphocytic leukaemia (CLL) has become a fertile testing ground for novel targeted agents, one of which may become the most lucrative haematology drug in history.
John Reed, Head of Pharma Research & Early Development at Roche, discusses his plans to tweak the therapeutic focus, clinical development strategy and externalization of innovation at Roche.
The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market.
Agents that target tumour-supportive cellular machineries, such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications, are emerging as a new wave of anticancer drugs. Here, Dobbelstein and Moll provide their perspective on the advantages and limitations of these agents compared with established drugs that target DNA replication or signalling proteins such as kinases.
This Review highlights recent progress in the development of ligands to target two classes of nuclear receptors — the REV-ERBs and retinoic acid receptor-related orphan receptors (RORs) — and describes how such ligands might be useful for treating disorders related to metabolism, immune function and the circadian rhythm.
The tumour suppressor p53 is the most frequently mutated gene in human cancer, and drugs that restore or activate the p53 pathway have now reached clinical trials. Most of these drugs inhibit MDM2, a negative regulator of p53. In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway and discuss the state of development of p53 pathway modulators.